Strategic Solutions to Commercial Complexity
Commercial Strategy, Due Diligence, and Value-Creation Planning for Radiopharmaceutical Assets
We advise biotech leaders, radiopharmaceutical developers, and institutional investors on the commercial realities that determine whether an asset becomes a market leader - or fails to meet its investment thesis.
Nearly 40 years of radiopharmaceutical industry leadership across commercialization, launch execution, supply chain strategy, and market development.
Trusted by biotech executives, investors, and boards evaluating high-stakes commercial decisions.
Why Clients Engage
When capital is deployed, commercial assumptions must be right
Theranostic & Radioligand Strategies helps leadership teams and investors answer the critical questions before decisions are locked in:
-
Is this asset commercially viable at scale?
-
What are the real barriers to adoption?
-
Where are the execution risks across supply chain and site readiness?
-
How can enterprise value be increased before financing, partnership, or exit?
Core Advisory Areas
Commercial Due Diligence
Independent evaluation of market opportunity, competitive positioning, commercial feasibility, and execution risk.
Commercialization Planning
End-to-end launch strategy grounded in market realities, operational feasibility, and investor expectations.
Supply Chain & Operational Readiness
Assessment of isotope sourcing, manufacturing scalability, site readiness, and delivery logistics.
Investor & Board Advisory
Strategic guidance for investment committees, boards, and executive teams making high-value decisions.
Who We Serve
-
Biotech and biopharma executive teams
-
Radiopharmaceutical developers
-
Private equity and venture capital firms
-
Strategic acquirers and business development teams
-
Boards and portfolio company leadership
Differentiation
A perspective few advisors can offer:
-
Experience spanning hospital, manufacturer, supply chain, clinical development, and executive leadership roles
-
Deep specialization in radiopharmaceutical and theranostics markets
-
Practical - not theoretical - commercial execution insight
-
Investor-grade diligence and strategic clarity
Testimonials
“Andy played a critical role in our radiotherapeutic launch readiness, integrating frontline clinical insight with supply chain and operational strategy. His contributions materially improved enterprise-level decision-making and reduced execution risk.”
- Chief Commercial Officer, Progenics Pharmacxeuticals
“Andy’s leadership and sustained engagement with our organization significantly accelerated our growth and impact. His deep expertise in launching transformative therapies and commitment to stakeholder alignment are best-in-class.”
- Founder & CEO, Veterans Prostate Cancer Awareness